The European Commission prohibited acquisition of GRAIL by Illumina as the merger would have stifled innovation and reduced choice in the market of blood based early cancer detection tests. The press release dated 6 August 2022 about the decision of the European Commission is available at https://ec.europa.eu/commission/presscorner/detail/en/ip_22_5364